Insulet (PODD) Stock Drops on Earnings Miss

NEW YORK (TheStreet) -- Insulet (PODD) shares fell sharply in intraday trading, down 9.65% to $26.97, on Friday after the insulin infusion company reported its first quarter earnings results after the closing bell yesterday.

The company reported a first quarter net loss of $11.8 million which translates to a net loss of 21 cents per share on an adjusted basis. The company generated revenue of $61.2 million.

Analysts on average were expecting the company to report a net loss of 11 cents per share on revenue of $68.3 million.

For the current quarter, the company is forecasting revenue between $67 million and $70 million while for the full year the company is guiding revenue between $305 million and $320 million.

TheStreet Ratings team rates INSULET CORP as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

"We rate INSULET CORP (PODD) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

PODD Chart PODD data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

If you liked this article you might like

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

Analysts' Actions -- Express Scripts, Lions Gate, Qorvo, Whole Foods and More

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Insulet (PODD) Is Strong On High Volume Today

On Tap for Analysts: Boston Scientific, Ford, Western Digital